Lung Cancer Considered

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu recap three important sessions from Tuesday, September 12th at the IASLC WCLC 2023:

Advocates Unite to Increase Lung Cancer Research Funding

An update on the AEGEAN Trial--Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable

Long-term Outcomes by Radiation Technique for Locally Advanced Non-Small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years

MARS 2 in Spanish--Monday WCLC Highlights

In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma.

Guests:

Dra. Rosanna Ruiz, Oncologo clínico

Institutio nacional de enfermedades neoplásicas, Lima, Peru

Dr. Ricardo Terra, Cirujano toracico

Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil

Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Emi Bossio, a patient research advocate and board member of Lung Cancer Canada adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer.

Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London.

Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan.

Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital

Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute

Sunday highlights from WCLC 2023 include hosts Dr. Narjust Florez and Dr. Stephen Liu discussing two-year data from KRYSTAL-1 with Dr. Shirish Gadgeel; a discussion of the IASLC Language Guide and patient-centered language with noted lung cancer patient advocate Jill Feldman; and six-year follow-up data from CheckMate 227 with Dr. Solange Peters.

Panelists:

Shirish Gadgeel, MD is the Associate Director of Henry Ford Cancer Institute and the Chief of Division of Hematology/Oncology at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University.

Jill Feldman, Lung Cancer Patient and Advocate, Twitter:

Solange Peters, MD, PhD Chair and Professor, Medical Oncology, Full Professor, University Hospital of Lausanne, Lausanne, Switzerland.

From lung cancer in women to gender equity in the healthcare workforce, IASLC is privileged to host HRH Princess Dina Mired of Jordan at the 2023 World Conference on Lung Cancer. In this special episode of Lung Cancer Considered, host Dr. Narjust Florez, IASLC President Dr. Heather Wakelee, and WCLC 2023 co-chair Dr. Fiona Hegi-Johnson discuss global advocacy through a gender equity lens, lessons learned from the field, and how HRH Dina Mired’s experience as the mother of a cancer survivor has impacted her work and initiatives globally.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general.

Guest: Dr. Vivek Subbiah

Dr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.

In this epidose of Lung Cancer Considered, Dr. Narjust Florez leads a discussion on the journey to an oncology fellowship.

Medical training is long, full of sacrifices and student debt for many. For our listeners, after graduating from pre-med or undergraduate studies future physicians need to complete 4 years of medical school, followed by 3 years of internal medicine residency or 5 years of surgery or radiation oncology residency. For internal medicine residents they need to complete 3 to 4 additional years of hematology and oncology fellowship.

Today we will be discussing recommendations for a smooth search, transition, and completion of an oncology fellowship.

Guests:

Dr. Christine Garcia, thoracic medical oncologist and fellowship program director at Weill Cornell Medicine in NYC.

Dr. Regina Barragan-Carrillo, who completed her medical oncology fellowship in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City and is currently a research fellow at City of Hope.

Dr. Jennifer Marks, chief oncology fellow at Georgetown University with a focus on thoracic oncology.

Lung Cancer Care in Mandarin: EGFR in China - From Testing to Treating by IASLC

Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations.

Guests:

Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society.

Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen’s University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.

Greece ranks third in mortality in Europe from lung cancer, surpassed by Hungary and Serbia. In this episode of Lung Cancer Considered, host Dr. Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at the Henry Dunant Hospital in Athens, Greece, leads a discussion on the efforts from the Hellenic scientific community to implement smoking cessation strategies, screening programs, multidisciplinary approach and personalized treatment approaches of the Greek patient with lung cancer.

Guests include:

Helena Linardou is a Medical Oncologist, is Director of the 4th Oncology Dept and the Comprehensive Clinical Trials Center of Metropolitan Hospital in Athens, Greece. She completed a research Fellowship in Oncology and obtained her PhD Degree from Imperial College, University of London, UK

Konstantinos Leventakos is a Medical Oncologist, assistant Professor at the Mayo Clinic in Rochester, USA, with a focus on thoracic malignancies, personalized medicine and immunotherapy.